<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814606</url>
  </required_header>
  <id_info>
    <org_study_id>16336A</org_study_id>
    <nct_id>NCT00814606</nct_id>
  </id_info>
  <brief_title>A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C</brief_title>
  <official_title>A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the safety and efficacy of taking fluvastatin along with&#xD;
      peginterferon alfa in previous partial responders with genotype 1 HCV.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no one ever enrolled&#xD;
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of adding fluvastatin to pegylated interferon alfa-2a and ribavirin in patients infected with genotype 1 HCV who are previous partial responders to standard treatment.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of adding fluvastatin to pegylated interferon alfa-2a and ribavirin in patients infected with genotype 1 HCV who are previous partial responders to standard treatment.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Single Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weeks period of escalating doses of fluvastatin to a goal dose of 80mg daily, then patients will start treatment of HCV at week 9 with the usual standard of care protocol for medication dose, office visits and laboratories. Peginterferon alfa2a 180 mcg/ml SQ injection once a week for 48 weeks and ribavirin 1000-1200 mg daily orally in two divided doses for 48 weeks. Patients weighing &lt; 75 kg will receive 1000mg per day (400mg in the morning and 600mg in the evening). Patients weighing ≥ 75 kg will receive 1200 mg per day (600mg in the morning and 600 mg in the evening).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvastatin</intervention_name>
    <description>Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily</description>
    <arm_group_label>Single Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa2a</intervention_name>
    <description>180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)</description>
    <arm_group_label>Single Group</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)</description>
    <arm_group_label>Single Group</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female of any ethnicity age 18 - 65 years with genotype 1 HCV&#xD;
&#xD;
          -  Previous partial responder to attempts at HCV therapy with PEG/RBV (at least 1 log&#xD;
             drop but less than 2 log drop in HCV RNA at 12 weeks)&#xD;
&#xD;
          -  Previous history or serum HCV-RNA PCR quantifiable by Roche Amplicore HCV Test&#xD;
&#xD;
          -  A liver biopsy within 3 years of study enrollment consistent with HCV disease.&#xD;
&#xD;
          -  Compensated liver disease, Child-Pugh Class ≤ 6&#xD;
&#xD;
          -  Negative urine pregnancy test (for women of childbearing potential) documented within&#xD;
             the 24-hour period prior to the first dose of the study drug&#xD;
&#xD;
          -  All patients enrolling in the study and all partners of study participants of&#xD;
             childbearing potential must be using two reliable forms of effective contraception&#xD;
             during the study. Exceptions may include partner/participant is surgically sterile.&#xD;
&#xD;
          -  Willingness to comply with study procedures and provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AST or ALT &gt; 10 ULN&#xD;
&#xD;
          -  Any investigational drug ≤ 12 weeks prior to the first of study drug&#xD;
&#xD;
          -  Prior intolerance to statin medications&#xD;
&#xD;
          -  Previous serious side effects to IFN or RBV (e.g. psychiatric side effect&#xD;
             necessitating treatment discontinuation, severe cytopenia refractory to growth&#xD;
             factors, intolerance to IFN/RBV requiring treatment discontinuation)&#xD;
&#xD;
          -  Any systemic antiviral therapy ≤ 24 weeks prior to the first dose of study drug or&#xD;
             expectation that such treatment will be needed at any time during the study.&#xD;
             Exception: Patients who have taken or are expected to require such treatment for&#xD;
             herpetic lesions&#xD;
&#xD;
          -  Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc-IgM Ab ,or anti-HIV Ab&#xD;
&#xD;
          -  Serum concentrations of cerulplamin or alph-1-antitrypsin consistent with an increased&#xD;
             risk of metabolic liver disease&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             (e.g. hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposure,&#xD;
             nonalcoholic steatohepatitis)&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding and male partners of woman who are pregnant or&#xD;
             breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K Gautham Reddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <last_update_submitted>June 28, 2013</last_update_submitted>
  <last_update_submitted_qc>June 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>genotype 1 hepatitis C</keyword>
  <keyword>hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

